Owners, management and financials
CVR: 41034076
EUR -85,226,000
Gross profit
Net result: EUR -110,131,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Jan Møller Mikkelsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 13 December 2019
CVR · view overview
0 employees
Annual report 2025 · average
Name registered: Ascendis Pharma Oncology Division A/S
CVR · 13/12/2019
View the full event history
Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -85.2 mio. EUR | -110.1 mio. EUR | - | -501.6 mio. EUR | 0 | |
| 202401/01/2024 – 31/12/2024 | -92.5 mio. EUR | -106.4 mio. EUR | 99 t. EUR | -391.5 mio. EUR | 0 | |
| 202301/01/2023 – 31/12/2023 | -140.1 mio. EUR | -144.1 mio. EUR | 457 t. EUR | -285.1 mio. EUR | 0 | |
| 202201/01/2022 – 31/12/2022 | -62.4 mio. EUR | -64.9 mio. EUR | 5.6 mio. EUR | -141 mio. EUR | 0 | |
| 202101/01/2021 – 31/12/2021 | -46.7 mio. EUR | -48 mio. EUR | 5.6 mio. EUR | -76.1 mio. EUR | 0 | |
| 202013/12/2019 – 31/12/2020 | -35.7 mio. EUR | -36.1 mio. EUR | 8.5 mio. EUR | -28.1 mio. EUR | 0 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Ascendis Pharma Oncology Division A/S is 41034076.
Ascendis Pharma Oncology Division A/S is owned by ASCENDIS PHARMA A/S.
The management of Ascendis Pharma Oncology Division A/S consists of Jan Møller Mikkelsen.
The board of Ascendis Pharma Oncology Division A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, Ascendis Pharma Oncology Division A/S reported a gross profit of EUR -85,226,000.
Ascendis Pharma Oncology Division A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Ascendis Pharma Oncology Division A/S has published its annual report for 2025. Gross profit came to DKK -85,226,000, and the net result was DKK -110,131,000.
Ascendis Pharma Oncology Division A/S has published its annual report for 2024. Gross profit came to DKK -92,475,000, and the net result was DKK -106,375,000.
Ascendis Pharma Oncology Division A/S has published its annual report for 2023. Gross profit came to DKK -140,146,399, and the net result was DKK -144,110,203.
Ascendis Pharma Oncology Division A/S has published its annual report for 2022. Gross profit came to DKK -62,367,388, and the net result was DKK -64,912,248.
Ascendis Pharma Oncology Division A/S has published its annual report for 2021. Gross profit came to DKK -46,676,711, and the net result was DKK -47,980,231.
Ascendis Pharma Oncology Division A/S has published its annual report for 2020. Gross profit came to DKK -35,705,202, and the net result was DKK -36,079,781.
As of December 13, 2019, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Ascendis Pharma Oncology Division A/S.
As of December 13, 2019, Michael Wolff Jensen has joined the board of directors of Ascendis Pharma Oncology Division A/S.
As of December 13, 2019, Jan Møller Mikkelsen has joined the board of directors of Ascendis Pharma Oncology Division A/S.
As of December 13, 2019, Anni Lotte Kirstine Pedersen has joined the board of directors of Ascendis Pharma Oncology Division A/S.
As of December 13, 2019, Jan Møller Mikkelsen is registered as director of Ascendis Pharma Oncology Division A/S.
As of December 13, 2019, ASCENDIS PHARMA A/S is registered as an owner of Ascendis Pharma Oncology Division A/S with an ownership share of 100%.
Ascendis Pharma Oncology Division A/S was founded on December 13, 2019.
Companies in the same industry and area
CVR 29918791
CVR 32323502
CVR 32323537
CVR 37011185
CVR 46029518
